ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,258.61
-0.40%
Dow Jones
44,860.31
0.28%
Gold vs US Dollar
2,638.39
0.23%
Brent Oil
72.39
-0.08%
Bitcoin
92,612.89
0.70%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Legend Biotech Corporation (LEGN)

  7. Legend Biotech Corporation (LEGN) News

Legend Biotech (LEGN)

Legend Biotech Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LEGN
DateTimeSourceHeadlineSymbolCompany
14/11/202413:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEGNLegend Biotech Corporation
12/11/202412:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
12/11/202412:00GlobeNewswire Inc.Legend Biotech Reports Third Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
07/11/202412:30GlobeNewswire Inc.Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LEGNLegend Biotech Corporation
05/11/202414:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
05/11/202414:10GlobeNewswire Inc.Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
04/11/202412:30GlobeNewswire Inc.Legend Biotech Appoints Alan Bash as President of CARVYKTI®NASDAQ:LEGNLegend Biotech Corporation
24/10/202412:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Third Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
22/10/202412:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
21/10/202420:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
15/10/202411:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
03/10/202411:30GlobeNewswire Inc.Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in PhiladelphiaNASDAQ:LEGNLegend Biotech Corporation
27/09/202420:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
27/09/202420:35GlobeNewswire Inc.CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second LineNASDAQ:LEGNLegend Biotech Corporation
25/09/202419:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/09/202420:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/09/202414:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/09/202412:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
27/08/202411:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
20/08/202412:00GlobeNewswire Inc.Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
09/08/202411:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
09/08/202411:00GlobeNewswire Inc.Legend Biotech Reports Second Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
09/08/202409:50IH Market NewsUS Futures Climb Following Thursday’s Rally, Oil Prices SteadyNASDAQ:LEGNLegend Biotech Corporation
08/08/202420:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
08/08/202420:05GlobeNewswire Inc.Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of DirectorsNASDAQ:LEGNLegend Biotech Corporation
26/07/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
26/07/202411:00GlobeNewswire Inc.Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024NASDAQ:LEGNLegend Biotech Corporation
17/07/202411:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
10/07/202412:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Second Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
02/07/202412:00GlobeNewswire Inc.Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN

Your Recent History

LSE
VAST
Vast Resources
LSE
GDR
Genedrive
LSE
SCLP
Scancell
LSE
BARC
Barclays
LSE
UPS
LSE
WTB
Whitbread
LSE
RIO
Rio Tinto
LSE
AEP
Anglo-eastern Plantations
LSE
EDEN
Eden Research
LSE
SLP
Sylvania Platinum
LSE
GKP
Gulf Keystone Petroleum
LSE
RR.
Rolls Royce
LSE
QBT
Quantum Blockchain Techn...
LSE
CAV
Cavendish Financial
LSE
STX
Shield Therapeutics
LSE
THUS
Thus
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Gold Trader

    1 year 35%, 2 years 45% and *3 years 60%

    *Across 3 years £3655.44 only £1462.17